Persistent IP-10/CXCL10 dysregulation following mild Omicron breakthrough infection: Immune network signatures across COVID-19 waves and implications for mRNA vaccine outcomes

dc.contributor.authorVacharathit V.
dc.contributor.authorPluempreecha M.
dc.contributor.authorManopwisedjaroen S.
dc.contributor.authorSrisaowakarn C.
dc.contributor.authorSrichatrapimuk S.
dc.contributor.authorSritipsukho P.
dc.contributor.authorSritipsukho N.
dc.contributor.authorThitithanyanont A.
dc.contributor.correspondenceVacharathit V.
dc.contributor.otherMahidol University
dc.date.accessioned2025-05-20T18:11:26Z
dc.date.available2025-05-20T18:11:26Z
dc.date.issued2025-09-01
dc.description.abstractThis study explores immune responses in mild Omicron-era COVID-19 breakthrough cases, focusing on cytokine dysregulation, antibody dynamics, and Long COVID. We analyzed samples from 114 mild symptomatic COVID-19 patients across multiple pandemic waves, each dominated by different SARS-CoV-2 variants, at three timepoints: (T1: 2–4 weeks, T2: 3–4 months, T3: 6–8 months post-infection). Persistent IP-10 elevation up to 8 months post–Omicron breakthrough infection suggests sustained low-grade immune activation that appears unique to this wave. Hybrid immunity from Omicron breakthrough infections elicited broad cross-variant antibody recognition but showed declining neutralization over time. Among vaccination regimens, mRNA-inclusive combinations were associated with lower Long COVID scores. CoV-229E antibody levels correlated with Long COVID scores. These findings underscore the need for extended monitoring of even mild COVID-19 cases and highlight the potential of mRNA vaccines in reducing post-COVID-19 complications. Insights into post-infection immune alterations and vaccine effects can inform the development of future vaccination strategies and approaches for managing post-COVID-19 conditions.
dc.identifier.citationClinical Immunology Vol.278 (2025)
dc.identifier.doi10.1016/j.clim.2025.110507
dc.identifier.eissn15217035
dc.identifier.issn15216616
dc.identifier.pmid40306350
dc.identifier.scopus2-s2.0-105004926163
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/110242
dc.rights.holderSCOPUS
dc.subjectMedicine
dc.subjectImmunology and Microbiology
dc.titlePersistent IP-10/CXCL10 dysregulation following mild Omicron breakthrough infection: Immune network signatures across COVID-19 waves and implications for mRNA vaccine outcomes
dc.typeArticle
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105004926163&origin=inward
oaire.citation.titleClinical Immunology
oaire.citation.volume278
oairecerif.author.affiliationFaculty of Science, Mahidol University
oairecerif.author.affiliationFaculty of Medicine Ramathibodi Hospital, Mahidol University
oairecerif.author.affiliationFaculty of Medicine, Thammasat University
oairecerif.author.affiliationThammasat University
oairecerif.author.affiliationDhurakij Pundit University

Files

Collections